| Item Type | Name |
|
Academic Article
|
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
|
|
Concept
|
Doxorubicin
|
|
Academic Article
|
Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer.
|
|
Academic Article
|
Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer.
|
|
Academic Article
|
Adriamycin and mitomycin C: possible synergistic cardiotoxicity.
|
|
Academic Article
|
Ten-year results of FAC adjuvant chemotherapy trial in breast cancer.
|
|
Academic Article
|
Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy.
|
|
Academic Article
|
Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs.
|
|
Academic Article
|
Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial.
|
|
Academic Article
|
Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute.
|
|
Academic Article
|
High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study.
|
|
Academic Article
|
Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy.
|
|
Academic Article
|
Management of inflammatory carcinoma of the breast. A combined modality approach.
|
|
Academic Article
|
Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy.
|
|
Academic Article
|
Use of Taxol (paclitaxel) in breast cancer.
|
|
Academic Article
|
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.
|
|
Academic Article
|
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.
|
|
Academic Article
|
Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer.
|
|
Academic Article
|
Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference.
|
|
Academic Article
|
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
|
|
Academic Article
|
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
|
|
Academic Article
|
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
|
|
Academic Article
|
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.
|
|
Academic Article
|
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
|
|
Academic Article
|
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
|
|
Academic Article
|
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.
|
|
Academic Article
|
Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.
|
|
Academic Article
|
Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer.
|
|
Academic Article
|
Electrocardiographic changes after adriamycin chemotherapy.
|
|
Academic Article
|
Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer.
|
|
Academic Article
|
Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma.
|
|
Academic Article
|
Adjuvant chemotherapy in high-risk breast cancer patients with ten or more positive lymph nodes.
|
|
Academic Article
|
Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience.
|
|
Academic Article
|
Multimodal treatment for inflammatory breast cancer.
|
|
Academic Article
|
Clinical course of breast cancer patients with liver metastases.
|
|
Academic Article
|
Phase II study of AMSA and doxorubicin to treat metastatic breast cancer.
|
|
Academic Article
|
Subclinical hepatic toxicity during combination chemotherapy for breast cancer.
|
|
Academic Article
|
Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.
|
|
Academic Article
|
Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial.
|
|
Academic Article
|
The management of locally advanced breast cancer: a combined modality approach.
|
|
Academic Article
|
Osteoblastic metastatic disease as a therapeutic response to adjuvant chemotherapy in breast cancer.
|
|
Academic Article
|
Management of inflammatory carcinoma of breast with combined modality approach - an update.
|
|
Academic Article
|
Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer.
|
|
Academic Article
|
Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine.
|
|
Academic Article
|
Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience.
|
|
Academic Article
|
Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome.
|
|
Academic Article
|
Management of breast cancer during pregnancy using a standardized protocol.
|
|
Academic Article
|
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.
|
|
Academic Article
|
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma.
|
|
Academic Article
|
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma.
|
|
Academic Article
|
A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility.
|
|
Academic Article
|
Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation.
|
|
Academic Article
|
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
|
|
Academic Article
|
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
|
|
Academic Article
|
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
|
|
Academic Article
|
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.
|
|
Academic Article
|
Adjuvant therapy of stage II, III breast cancer.
|
|
Academic Article
|
Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG.
|
|
Academic Article
|
Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy.
|
|
Academic Article
|
Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG.
|
|
Academic Article
|
Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report.
|
|
Academic Article
|
Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED).
|
|
Academic Article
|
Chemo immunotherapy of advanced breast cancer with BCG.
|
|
Academic Article
|
Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer.
|
|
Academic Article
|
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
|
|
Academic Article
|
Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy.
|
|
Academic Article
|
Pirarubicin in combination chemotherapy for metastatic breast cancer.
|
|
Academic Article
|
Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer?
|
|
Academic Article
|
Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients.
|
|
Academic Article
|
Role of adjuvant chemotherapy in male breast cancer.
|
|
Academic Article
|
Bilateral primary breast cancer in patients treated with adjuvant therapy.
|
|
Academic Article
|
Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer.
|
|
Academic Article
|
Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute.
|
|
Academic Article
|
Second neoplasms after adjuvant chemotherapy for operable breast cancer.
|
|
Academic Article
|
Management of locoregional recurrent breast cancer.
|
|
Academic Article
|
Early and delayed clinical cardiotoxicity of doxorubicin.
|
|
Academic Article
|
Comment on 'Long-term tamoxifen adjuvant therapy in node positive breast cancer'.
|
|
Academic Article
|
Combined modality approach in breast cancer with isolated or multiple metastases.
|
|
Academic Article
|
Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer.
|
|
Academic Article
|
FAC + BCG as adjuvant therapy in breast cancer: an 8-year update.
|
|
Academic Article
|
Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone.
|
|
Academic Article
|
Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate.
|
|
Academic Article
|
Multivariate analysis of prognostic factors in metastatic breast cancer.
|
|
Academic Article
|
Multimodal treatment of locoregionally advanced breast cancer.
|
|
Academic Article
|
Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer.
|
|
Academic Article
|
Estrogen receptor: a prognostic factor in breast cancer.
|
|
Academic Article
|
Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens.
|
|
Academic Article
|
Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy.
|
|
Academic Article
|
Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer.
|
|
Academic Article
|
Present status of anthracyclines in the adjuvant treatment of breast cancer.
|
|
Academic Article
|
The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.
|
|
Academic Article
|
Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.
|
|
Academic Article
|
Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma.
|
|
Academic Article
|
Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer.
|
|
Academic Article
|
Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer.
|
|
Academic Article
|
The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy.
|
|
Academic Article
|
Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature.
|
|
Academic Article
|
Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
|
|
Academic Article
|
Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience.
|
|
Academic Article
|
Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
|
|
Academic Article
|
The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy.
|
|
Academic Article
|
Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
|
|
Academic Article
|
A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.
|
|
Academic Article
|
The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.
|
|
Academic Article
|
Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
|
|
Academic Article
|
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
|
|
Academic Article
|
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
|
|
Academic Article
|
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results.
|
|
Academic Article
|
Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma.
|
|
Academic Article
|
Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole.
|
|
Academic Article
|
Drug-associated cardiotoxicity.
|
|
Academic Article
|
Complete remissions in metastatic breast cancer treated with combination drug therapy.
|
|
Academic Article
|
Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Gu?rin.
|
|
Academic Article
|
Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma.
|
|
Academic Article
|
Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
|
|
Academic Article
|
Noninvasive cardiac evaluation of patients receiving adriamycin-containing adjuvant chemotherapy (FAC) for stage II or III breast cancer.
|
|
Academic Article
|
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
|
|
Academic Article
|
Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.
|
|
Academic Article
|
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation.
|
|
Academic Article
|
Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.
|
|
Academic Article
|
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
|
|
Academic Article
|
Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control.
|
|
Academic Article
|
Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer.
|
|
Academic Article
|
Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base.
|
|
Academic Article
|
Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio.
|
|
Academic Article
|
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
|
|
Academic Article
|
Impact of patient characteristics on treatment outcome: anthracycline resistance.
|
|
Academic Article
|
Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma.
|
|
Academic Article
|
The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
|
|
Academic Article
|
Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence.
|
|
Academic Article
|
Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy.
|
|
Academic Article
|
Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer.
|
|
Academic Article
|
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
|
|
Academic Article
|
Non-invasive cardiac studies before and after adriamycin-containing adjuvant chemotherapy (FAC) for stages II and III breast cancer
|
|
Academic Article
|
An intensive new adjuvant chemoimmunotherapy program containing 5 fluorouracil (5 FU), adriamycin (AD), cyclophosphamide (CYT), and BCG (FAC BCG) for operable breast cancer
|
|
Academic Article
|
A comparative randomized trial of doxorubicin and cyclophosphamide in combination with fluorouracil (FAC) or etoposide (EAC) in metastatic breast cancer
|
|
Academic Article
|
Reutilization of doxorubicin in patients with progressive metastatic breast cancer
|
|
Academic Article
|
Postoperative Adjuvant Chemotherapy With Fluorouracil, Doxorubicin, Cyclophosphamide, and BCG Vaccine
|
|
Academic Article
|
Adriamycin and mitomycin-C - possible synergistic cardiotoxicity
|
|
Academic Article
|
Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC) in stage II or III breast cancer; 5-year results
|
|
Academic Article
|
Adjuvant chemotherapy for breast cancer with fluorouracil, adriamycin, cyclophosphamide (FAC) with or without BCG and with or without post-operative irradiation (XRT). A prospective randomized study
|